Diagnostics (May 2022)

The Use of <sup>18</sup>F-FET-PET-MRI in Neuro-Oncology: The Best of Both Worlds—A Narrative Review

  • Tineke van de Weijer,
  • Martijn P. G. Broen,
  • Rik P. M. Moonen,
  • Ann Hoeben,
  • Monique Anten,
  • Koos Hovinga,
  • Inge Compter,
  • Jochem A. J. van der Pol,
  • Cristina Mitea,
  • Toine M. Lodewick,
  • Arnaud Jacquerie,
  • Felix M. Mottaghy,
  • Joachim E. Wildberger,
  • Alida A. Postma

DOI
https://doi.org/10.3390/diagnostics12051202
Journal volume & issue
Vol. 12, no. 5
p. 1202

Abstract

Read online

Gliomas are the most frequent primary tumors of the brain. They can be divided into grade II-IV astrocytomas and grade II-III oligodendrogliomas, based on their histomolecular profile. The prognosis and treatment is highly dependent on grade and well-identified prognostic and/or predictive molecular markers. Multi-parametric MRI, including diffusion weighted imaging, perfusion, and MR spectroscopy, showed increasing value in the non-invasive characterization of specific molecular subsets of gliomas. Radiolabeled amino-acid analogues, such as 18F-FET, have also been proven valuable in glioma imaging. These tracers not only contribute in the diagnostic process by detecting areas of dedifferentiation in diffuse gliomas, but this technique is also valuable in the follow-up of gliomas, as it can differentiate pseudo-progression from real tumor progression. Since multi-parametric MRI and 18F-FET PET are complementary imaging techniques, there may be a synergistic role for PET-MRI imaging in the neuro-oncological imaging of primary brain tumors. This could be of value for both primary staging, as well as during treatment and follow-up.

Keywords